Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess the Safety and Clinical Efficacy of MBM-02 to Increase Survival in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT04874506 is registered in ClinicalTrials.gov with Matrix Biomed, Inc. as lead sponsor.

NCT NCT04874506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04874506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess the Safety and Clinical Efficacy of MBM-02 to Increase Survival in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
Lead sponsor
Matrix Biomed, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2021
Completion date
August 31, 2023
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme